Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
PHASE2Not yet recruitingINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
June 15, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
January 31, 2027
Conditions
Metastatic Breast Cancer in the Brain
Interventions
DRUG
pyrotinib plus capecitabine
oral
All Listed Sponsors
lead
Henan Cancer Hospital
OTHER_GOV
NCT06475443 - Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs | Biotech Hunter | Biotech Hunter